Letter from the Editor

Home > Dermatology > AAD 2020

American Academy of Dermatology Virtual Meeting Experience; 12–14 June 2020; Edited by Prof. Peter van de Kerkhof (Radboudumc, the Netherlands).

Letter from the Editor

Editor

Prof. Peter van de Kerkhof, Radboudumc, the Netherlands

AAD 2020 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Late-Breaking Abstracts

IL-17A and IL-17F blockade remarkably effective in psoriasis

Presented By

Prof. Kristian Reich; Prof. Kenneth B. Gordon

Good response and pruritus reduction in AD with novel selective JAK1 inhibitor

Presented By

Dr Melinda Gooderham

Novel IL-23 blocker risankizumab highly effective and tolerable in psoriasis

Presented By

Prof. Richard B. Warren

IL-13 blocker tralokinumab effective in AD

Presented By

Prof. Eric Simpson

Tape stripping – a painless way to distinguish AD and psoriasis?

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada

IL-4/IL-13 blocker dupilumab effective in children with severe AD

Presented By

Prof. Amy S. Paller, Northwestern University Feinberg School of Medicine, USA

Pembrolizumab leads to higher toxicity risk in obese melanoma patients

Presented By

Ms Surya Ravichandran, Duke University, USA

Can gene expression help to pick the right biologic to treat psoriasis in cancer patients?

Presented By

Dr Nikolai Klebanov , Brigham and Women’s Hospital, USA

Omalizumab for cancer-induced dermatoses

Presented By

Ms Dulce M. Barrios, Memorial Sloan Kettering Cancer Center (USA)

Psoriasis – What Is Hot?

Psoriasis therapy for children and pregnancies

Presented By

Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, USA

Biologic psoriasis treatment to lower cardiovascular risk?

Presented By

Prof. Joel Gelfand, University of Pennsylvania, USA

A new topical PDE-4 inhibitor effective in psoriasis

Presented By

Prof. Mark Lebwohl

Systemic Therapies for Dermatologists

How to manage cutaneous side effects of immunotherapy

Presented By

Prof. Jennifer N. Choi, Northwestern Feinberg School of Medicine, USA

Cannabinoids: a future role in dermatology?

Presented By

Prof. Adam Friedman, School of Medicine & Health Sciences, USA

Hidradenitis Suppurativa/Acne Inversa

HS patients carry higher risk for systemic lupus erythematosus

Biologics in HS – a growing armamentarium

Presented By

Prof. Joslyn Kirby, Penn State University, USA

Pearls of the Posters

Selective IL-23 blocker safe in elderly psoriasis patients

Presented By

Prof. Peter van de Kerkhof, Radboudumc, the Netherlands

Spironolactone safe for androgenetic alopecia in cancer survivors

Presented By

Dr Chapman Wei, George Washington University, USA

Baricitinib beneficial in head and neck AD

Presented By

Dr Eric Simpson, Oregon Health and Science University, USA

Continuous terbinafine most effective for toenail onychomycosis

Presented By

Dr N Stec

ECLIPSE trial: skin clearance independent of PsA status at baseline

Presented By

Prof. Kristian Reich

Medical Conferences

AAD 2020

Table of Contents

Featured articles

Letter from the Editor

AAD 2020 Highlights Podcast

Late-Breaking Abstracts

IL-17A and IL-17F blockade remarkably effective in psoriasis

Good response and pruritus reduction in AD with novel selective JAK1 inhibitor

Novel IL-23 blocker risankizumab highly effective and tolerable in psoriasis

IL-13 blocker tralokinumab effective in AD

Tape stripping – a painless way to distinguish AD and psoriasis?

IL-4/IL-13 blocker dupilumab effective in children with severe AD

Pembrolizumab leads to higher toxicity risk in obese melanoma patients

Can gene expression help to pick the right biologic to treat psoriasis in cancer patients?

Omalizumab for cancer-induced dermatoses

Psoriasis – What Is Hot?

Psoriasis therapy for children and pregnancies

Biologic psoriasis treatment to lower cardiovascular risk?

A new topical PDE-4 inhibitor effective in psoriasis

Systemic Therapies for Dermatologists

How to manage cutaneous side effects of immunotherapy

Cannabinoids: a future role in dermatology?

Hidradenitis Suppurativa/Acne Inversa

HS patients carry higher risk for systemic lupus erythematosus

Biologics in HS – a growing armamentarium

Pearls of the Posters

Selective IL-23 blocker safe in elderly psoriasis patients

Spironolactone safe for androgenetic alopecia in cancer survivors

Baricitinib beneficial in head and neck AD

Continuous terbinafine most effective for toenail onychomycosis

ECLIPSE trial: skin clearance independent of PsA status at baseline

Intranasal kappa-opioid agonist effective for intractable pruritus

Better compliance in AD skin care with novel emollient stick